Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525910 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
A Phase 1 study of Healthy Participants and Biological Availability, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05525910 is a Phase 1 study of Healthy Participants and Biological Availability that has completed, run by Pfizer. The registered enrollment target is 15 participants, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05525910, a Phase 1 study of Healthy Participants and Biological Availability, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult participants.
Conditions Studied
Interventions
- DRUG Nirmatrelvir/ ritonavir
- DRUG Nirmatrelvir/ritonavir
Study Locations (1)
Connecticut
- New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05525910
The ClinicalTrials.gov registry entry for NCT05525910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (77% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Nirmatrelvir/ ritonavir is the first listed.
NCT05525910 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05525910 about?
NCT05525910 is a clinical study titled "Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants". The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult participants.
What is the current status of trial NCT05525910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-08-31. Estimated completion is 2022-11-07.
What conditions does trial NCT05525910 study?
This clinical trial studies the following conditions: Healthy Participants, Biological Availability.
What interventions are being tested in trial NCT05525910?
The interventions under investigation include: Nirmatrelvir/ ritonavir (DRUG), Nirmatrelvir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT05525910?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05525910 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.